This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2003 human-pharmacology trial that measured when ayahuasca’s acute effects emerged and how they corresponded with blood concentrations of major alkaloids and cardiovascular measures. Eighteen healthy adults with prior experience participated, comparing two conditions of a freeze-dried, encapsulated research preparation with placebo under double-blind conditions. The study examined acute time courses and pharmacokinetics, not clinical therapeutic effects.
Study design
Participants received each condition on different study days. Subjective ratings, blood pressure, heart rate, pupil diameter, blood levels of DMT and harmine-related compounds, urinary monoamine metabolites, and other measures were recorded over time. Because the research sample had been chemically analyzed, exposure conditions could be related to measurements. The study was not designed to estimate the composition of brews in circulation.
Double-blind placebo control is useful for comparing acute changes, although the strong subjective effects may have allowed participants to infer allocation. Participants had previous experience and do not represent first-time users or people with medical conditions.
Content
Subjective effects increased after ingestion and generally became strongest around 1.5–2 hours afterward. The time course of blood DMT concentrations was also measured, and the mean time to peak DMT concentration was reported as approximately 1.5 hours. Harmine underwent substantial peripheral metabolism, leading to an interpretation that the principal role in making oral DMT available occurs in the gastrointestinal tract and liver.
Among cardiovascular measures, a mean increase in diastolic blood pressure was reported under the higher research condition. Even if a mean change is relatively small, that cannot establish safety in situations involving individual variation, underlying disease, or concomitant medication. Changes in monoamine metabolites provide supporting information for understanding β-carboline activity, but they do not explain psychological experience or clinical outcomes through a single pathway.
Results
The study showed the temporal relationship among acute subjective effects, blood alkaloid concentrations, and cardiovascular responses after ayahuasca. It is important for supporting with human data the pharmacological framework in which orally administered DMT is detectable and β-carboline constituents participate in its metabolism.
The findings, however, describe a compositionally standardized freeze-dried sample, selected experienced participants, and observation within a facility. They do not demonstrate therapeutic efficacy, long-term safety, or equivalence with traditional preparations.
Limitations
The sample consisted of 18 healthy, experienced participants. The study cannot evaluate rare reactions, long-term change, repeated exposure, different brews, or people with psychiatric or cardiovascular conditions. Functional unblinding due to distinctive subjective effects is also possible.
Average measured blood concentrations did not correspond perfectly with each individual’s subjective effects, and differences in body size, metabolism, and prior experience remain. The research capsules also differed from traditional brews in taste and mode of ingestion, and the study did not assess psychosocial elements of ceremonial settings.
Safety
Changes in blood pressure and heart rate, nausea, vomiting, and acute anxiety cannot be judged from averages in healthy adults alone. Because β-carbolines act on monoamine oxidase, interactions with other drugs are important. This page does not provide guidance on amounts or methods of ingestion.
Source and rights
Original source: Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics. 2003;306(1):73–83. DOI: 10.1124/jpet.103.049882.
This page is a detailed introduction based on publicly available bibliographic information and the abstract; it is not a translation or republication of the original article. Consult the original for precise analytical methods, numbers, and statistics.